Abstracts Archive - Page 828 of 2607 - ACR Meeting Abstracts

Abstract Number: 1843 • ACR Convergence 2021
Perceptions and Concerns Regarding COVID-19 Vaccination in Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
Jessica Gordon¹, Kimberly Showalter¹, Yin Wu², Linda Kwakkenbos³, Marie-Eve Carrier⁴, Richard Henry², Nora Østbø², Julia Nordlund², Angelica Bourgeault², Mara Canedo Ayala², Marie-Nicole Discepola², Andrea Carboni Jiménez², Christopher Denton⁵, Luc Mouthon⁶, Brett Thombs⁷ and Robert Spiera¹, ¹Hospital for Special Surgery, New York, NY, ²Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada, ³Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁶Hopital Cochin - Paris University, Paris, France, ⁷Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada
Background/Purpose: Hesitancy about COVID-19 vaccination exists among patients with rheumatic and musculoskeletal diseases, but previous studies have not assessed this specifically in patients with systemic…
Abstract Number: 1844 • ACR Convergence 2021
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated ILD (SSc-ILD) and Differing Comorbidity Burden: Subgroup Analyses of the SENSCIS Trial
Kristin B Highland¹, Teng Moua², Martin Aringer³, Takashi Ogura⁴, Corinna Miede⁵, Margarida Alves⁶ and Virginia Steen⁷, ¹Cleveland Clinic, Cleveland, OH, ²Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, ³Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, ⁴Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Centre, Yokohama, Japan, ⁵mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach, Germany, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁷Division of Rheumatology, Georgetown University, Washington, DC
Background/Purpose: In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) vs placebo. Patients with SSc-ILD…
Abstract Number: 1845 • ACR Convergence 2021
Six-minute Walk Test as a Prognostic Marker in Systemic Sclerosis
Vinicius Verlangieri Soubihe, Juliana Zonzini Gaino, Alisson Pugliesi, Ana Paula Toledo Del Rio, Zoraida Sachetto, Marília Paula Souza Dos Santos and Luciana Campanatti Palhares, University of Campinas, Campinas, Brazil
Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the leading causes of mortality in systemic sclerosis (SSc). Although the six-minute walk test…
Abstract Number: 1846 • ACR Convergence 2021
Effect of Nintedanib in Patients with Systemic Sclerosis-associated Interstitial Lung Disease and Risk Factors for Rapid Decline in Forced Vital Capacity: Further Analyses of the SENSCIS Trial
Dinesh Khanna¹, Toby M Maher², Elizabeth Volkmann³, Yannick Allanore⁴, Vanessa Smith⁵, Shervin Assassi⁶, Michael Kreuter⁷, Anna-Maria Hoffmann-Vold⁸, Masataka Kuwana⁹, Christian Stock¹⁰, Margarida Alves¹¹, Steven Sambevski¹¹ and Christopher Denton¹², ¹University of Michigan, Ann Arbor, MI, ²National Heart and Lung Institute, Imperial College London, UK, National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, and Keck School of Medicine, University of Southern California, Los Angeles, CA, ³Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA, ⁴Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, ⁵Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent, Belgium, ⁶University of Texas McGovern Medical School at Houston, Houston, TX, ⁷Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany, ⁸Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹⁰Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ¹¹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ¹²University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: In the SENSCIS trial conducted in a population of subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD), with a mean time since onset of…
Abstract Number: 1847 • ACR Convergence 2021
Severity of Gastroesophageal Reflux, but Not the Use of Proton Pump Inhibitors, Is Associated with Radiographic Progression of Interstitial Lung Disease in Systemic Sclerosis
Elizabeth Volkmann¹, Donald Tashkin², Mei Leng², Grace Kim², Jonathan Goldin² and Michael Roth², ¹Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA
Background/Purpose: Esophageal dysmotility is a common feature of systemic sclerosis (SSc) and aspiration of gastric contents may serve as an inciting and/or exacerbating factor in…
Abstract Number: 1848 • ACR Convergence 2021
Untangling the Gut: A Phenome-Wide Association Study of Drugs and Diseases with Gastrointestinal Dysfunction in Systemic Sclerosis
Rory Maclean¹, Fiza Ahmed², Voon Ong³, Charles Murray⁴ and Christopher Denton⁵, ¹Royal Free Hospital & University College London, London, United Kingdom, ²Royal Free Hospital, Ilford, United Kingdom, ³University College London Medical School Royal Free Campus, London, United Kingdom, ⁴Royal Free Hospital, London, United Kingdom, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Gastrointestinal dysfunction (SSc-GI) is a significant burden to patients with systemic sclerosis (SSc), particularly in those with longstanding disease. The management of SSc-GI is…
Abstract Number: 1849 • ACR Convergence 2021
False Positive Anti-Topoisomerase I (Scl-70) Antibody Results: A Case Series from a Scleroderma Referral Center
Brian Lam¹, Rana Taherian¹, Julio Charles¹, Maureen Mayes², Shervin Assassi³ and Brian Skaug⁴, ¹Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX, ²Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ³University of Texas McGovern Medical School at Houston, Houston, TX, ⁴University of Texas McGovern Medical School Houston, Houston, TX
Background/Purpose: Systemic sclerosis (SSc) is a progressive autoimmune disease with high morbidity and mortality, making early diagnosis and management critical. Anti-Topoisomerase I antibody (anti-Topo I,…
Abstract Number: 1850 • ACR Convergence 2021
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Two-Year Data from SENSCIS-ON
Yannick Allanore¹, Madelon C Vonk², Oliver Distler³, Arata Azuma⁴, Maureen Mayes⁵, Martina Gahlemann⁶, Alexandra James⁷, Veronika Kohlbrenner⁸, Margarida Alves⁹, Dinesh Khanna¹⁰ and Kristin B Highland¹¹, ¹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ⁴Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁶Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁷Elderbrook solutions GmbH, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, ⁸Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, ⁹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Cleveland Clinic, Cleveland, OH
Background/Purpose: In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52 weeks by…
Abstract Number: 1851 • ACR Convergence 2021
Early Intervention with Immunomodulators Leads to Better Outcomes in Patients with Systemic Sclerosis
Keina Yomono¹ and Masataka Kuwana², ¹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a complex disease characterized by microvascular abnormalities, immune dysregulation and chronic inflammation, and subsequent excessive fibrosis of the skin and…
Abstract Number: 1852 • ACR Convergence 2021
Healthcare Utilization and Economic Burden in Systemic Sclerosis
Leonardo Martin Calderon¹, Mitali Chaudhary¹ and Janet Pope², ¹Western University, London, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Systemic Sclerosis (SSc) is a multi-system autoimmune disease, characterized by vasculopathy, fibrosis of the skin and internal organs, and autoimmunity with distinct antibodies. SSc…
Abstract Number: 1853 • ACR Convergence 2021
Scleroderma Presentation in the Canadian Scleroderma Research Group Indigenous Population
Curtis Sobchak, Karen Beattie and Maggie Larche, McMaster University, Hamilton, ON, Canada
Background/Purpose: Given the well-known burden of rheumatic disease in Canadian Indigenous populations, the Canadian Rheumatology Association (CRA) has highlighted Aboriginal Rheumatology as an area needing…
Abstract Number: 1854 • ACR Convergence 2021
Disease Characteristics and Social Determinants in African Americans with Systemic Sclerosis: A Single Center Experience
Sarah Compton, DeAnna Baker Frost, Richard Silver and Diane Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease categorized on the basis of skin involvement as either limited or diffuse cutaneous SSc, the latter…
Abstract Number: 1855 • ACR Convergence 2021
Up-regulation of TNFα Gene in Peripheral Blood Is Useful for Predicting the Development of Exercise-induced Pulmonary Hypertension, Which Is Early Stage of Pulmonary Vascular Disease Associated with Systemic Sclerosis
Yoshinobu Koyama¹, Yoshiharu Sato², Tatsuma Shoji², Soichiro Fuke¹, Takatsune Umayahara¹ and Moe Sakamoto¹, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan
Background/Purpose: Pulmonary hypertension (PH) is prominent as a vascular involvement of systemic sclerosis (SSc), which remains a leading cause of death in spite of current…
Abstract Number: 1856 • ACR Convergence 2021
Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous SSc
Ranjitha Karanth¹, Giuseppina Abignano², Vishal Kakkar², Rebecca Ross², Christopher Denton³ and Francesco Del Galdo², ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, LTHT, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) carries a highly variable prognosis and to date there are no stratification tools to predict clinical outcomes. Evidence suggests…
Abstract Number: 1857 • ACR Convergence 2021
Ultra-High Frequency Ultrasound Compared to Durometry and Skin Score for Cutaneous Assessment in Systemic Sclerosis
Marco Di Battista¹, Saverio Vitali², Simone Barsotti³, Alessandra Della Rossa⁴, Valentina Dini⁵, Marco Romanelli⁵ and Marta Mosca³, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Radiology Unit - University of Pisa, Pisa, Italy, ³Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁴Rheumatology Unit - University of Pisa, Pisa, Italy, ⁵Dermatology Unit - University of Pisa, Pisa, Italy
Background/Purpose: To assess skin involvement in a cohort of patients with systemic sclerosis (SSc) comparing results obtained from modified Rodnan skin score (mRSS), durometry and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].